publication date: May. 10, 2019

NCI approves Georgetown-Hackensack consortium

Are more long-distance relationships in the works?

By Paul Goldberg

NCI has funded a consortium uniting Georgetown Lombardi Cancer Center and  John Theurer Cancer Center of Hackensack University Medical Center.

The institute’s action, which comes as part of renewal of Georgetown’s NCI Comprehensive Cancer Center designation, may have far-reaching ramifications, because it recognizes union of two institutions separated by four state lines and 233 miles.

“The idea that you had to be contiguous is no longer true,” said Andrew L. Pecora, president of Physician Enterprise, chief innovations officer at Hackensack Meridian Health, and professor of medicine and oncology at Georgetown.

Whereas previously a cancer center consortium had been largely defined by some form of cohesive geography, such as the Harvard Cancer Center being primarily based in Boston, with the Harvard institutions, the UCSD consortium being placed largely in the San Diego region, and other consortia being made with the statewide collaboration in a geographical state, ours represents a collaboration between two organizations that are based in different states and separated by 233 miles, with different cultures and histories,” Louis M. Weiner, director of Georgetown Lombardi and MedStar Georgetown Cancer Institute, and Francis L. and Charlotte G. Gragnani Chair in oncology, said to The Cancer Letter.

A conversation with Weiner and Pecora is posted here.

According to NCI, 17 cancer centers currently operate as consortia, though this number can fluctuate from review cycle to cycle. A list of the consortia appears below.

story1-1Continue reading NCI approves Georgetown-Hackensack consortium Are more long-distance relationships in the works?

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.